KA/EN
Register
Medicines reference
Search
Search
Product

NexGard Spectra

Favourites

Afoxolaner + Milbemycin oxime · Boehringer Ingelheim

5 forms: chewable tablet. In force in Georgia: 5 of 5 (veterinary register).

Forms and doses5 of 5 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Weight Dose Frequency Georgia
9 mg/2 mg, Chewable tablet · Cat Any weight Cat Any weight No dose for this species
Dogs.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნექსგარდი სპექტრა - 2-3,5კგ ძაღლებისთვის
№ 40-11, 453-11, 173-11
Verified on: 15 Oct 2026
9 mg/2 mg, Chewable tablet · Dog 1.35–3.5 kg Dog 1.35–3.5 kg 1 tablet
a dose of 2.50 to 6.94 mg/kg of afoxolaner and 0.50 to 1.39 mg/kg of milbemycin oxime only indicated when use against ticks, fleas, or mites and one or more of the other target parasites is indicated at the same time The recommended dose should be strictly observed in collies or related breeds. use only according to the benefit-risk assessment
 · monthly		 monthly Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნექსგარდი სპექტრა - 2-3,5კგ ძაღლებისთვის
№ 40-11, 453-11, 173-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

NexGard Spectra 9 mg/2 mg, Chewable tablet

afoxolaner 9.375 mg + milbemycin oxime 1.875 mg, chewable tablet for dogs 1.35-3.5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.5/10
Very good
vetman assessment

NexGard Spectra

9 mg/2 mg, afoxolaner 9.375 mg + milbemycin oxime 1.875 mg, chewable tablet for dogs 1.35-3.5 kg
Assessed clinical scopeDog · Full labelled canine mixed-parasite scope, only when flea or tick control and one or more other labelled parasite targets are indicated at the same time · By mouth
Care settingVeterinary-selected monthly or indication-specific integrated parasite control after diagnosis and exposure-risk assessment
vetman score 8.5/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 40-11, 453-11, 173-11 · Verified on 15 Oct 2026

A strong broad-spectrum canine option when ectoparasite control and an additional labelled nematode target coincide; avoid using the fixed combination when one component adds no clinical value.

Regulatory and scientific credibility9.5/10

All five exact weight bands are centrally authorised in the EU, covered by a current official SPC and registered in Georgia, with an extensive indication-specific evidence package.

Clinical efficacy9.0/10

Controlled and field studies support high efficacy across major labelled fleas, ticks, mites and nematodes, including heartworm and lungworm prevention; the fixed combination is justified only when both components are clinically needed.

Safety and tolerability7.0/10

Usually well tolerated, but isoxazoline-associated neurologic reactions, macrocyclic-lactone susceptibility, heartworm screening, young or underweight dogs and unestablished reproductive safety require deliberate case selection.

Clinical practicality8.5/10

A palatable monthly whole chew and clear weight bands are convenient in practice, but the tablet cannot be divided and the indication, body weight, heartworm status and treatment interval must be checked.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only when flea or tick control and one or more other labelled parasite targets are indicated simultaneously; avoid the fixed combination when one active component is unnecessary.
  • In heartworm-endemic areas, test dogs before administration; the product does not kill adult heartworms and infected dogs require specialist management.
  • Use caution in dogs with a history of seizures or neurologic disorders and strictly observe the recommended dose in Collies and related breeds.
  • For dogs younger than 8 weeks or below 1.35 kg, use only after an individual benefit-risk assessment; safety in breeding males and during pregnancy or lactation is not established.
Assessment sources
  1. VMD SPC 20262026
  2. EMA NexGard Spectra EPAR2025
  3. NexGard Spectra GI nematode RCTs2016
  4. NexGard Spectra lungworm RCT2016
  5. NexGard Spectra sarcoptic field study2018
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Afoxolaner9.375 mg Milbemycin oxime1.875 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Boehringer Ingelheim · Germany
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნექსგარდი სპექტრა - 2-3,5კგ ძაღლებისთვის
№ 40-11, 453-11, 173-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
Dogs.
 Cat Any weight By mouth - Product label (SPC)
1 tablet
a dose of 2.50 to 6.94 mg/kg of afoxolaner and 0.50 to 1.39 mg/kg of milbemycin oxime only indicated when use against ticks, fleas, or mites and one or more of the other target parasites is indicated at the same time The recommended dose should be strictly observed in collies or related breeds. use only according to the benefit-risk assessment
 Dog 1.35–3.5 kg By mouth monthly Product label (SPC)
19 mg/4 mg, Chewable tablet · Cat Any weight Cat Any weight No dose for this species
Dogs.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნექსგარდი სპექტრა ->3,5-7,5კგ ძაღლებისთვის
№ 41-11, 351-11
Verified on: 15 Oct 2026
19 mg/4 mg, Chewable tablet · Dog 3.5–7.5 kg Dog 3.5–7.5 kg 1 tablet
For dogs above 3.5–7.5 kg, give 1 NexGard Spectra 19 mg/4 mg tablet. Use only for mixed infestations. In Collies and related breeds, follow the dose exactly. Test first in heartworm-endemic areas. Do not divide the tablet.
 · monthly		 monthly Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნექსგარდი სპექტრა ->3,5-7,5კგ ძაღლებისთვის
№ 41-11, 351-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

NexGard Spectra 19 mg/4 mg, Chewable tablet

afoxolaner 18.75 mg + milbemycin oxime 3.75 mg, chewable tablet for dogs 3.5-7.5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.5/10
Very good
vetman assessment

NexGard Spectra

19 mg/4 mg, afoxolaner 18.75 mg + milbemycin oxime 3.75 mg, chewable tablet for dogs 3.5-7.5 kg
Assessed clinical scopeDog · Full labelled canine mixed-parasite scope, only when flea or tick control and one or more other labelled parasite targets are indicated at the same time · By mouth
Care settingVeterinary-selected monthly or indication-specific integrated parasite control after diagnosis and exposure-risk assessment
vetman score 8.5/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 41-11, 351-11 · Verified on 15 Oct 2026

A strong broad-spectrum canine option when ectoparasite control and an additional labelled nematode target coincide; avoid using the fixed combination when one component adds no clinical value.

Regulatory and scientific credibility9.5/10

All five exact weight bands are centrally authorised in the EU, covered by a current official SPC and registered in Georgia, with an extensive indication-specific evidence package.

Clinical efficacy9.0/10

Controlled and field studies support high efficacy across major labelled fleas, ticks, mites and nematodes, including heartworm and lungworm prevention; the fixed combination is justified only when both components are clinically needed.

Safety and tolerability7.0/10

Usually well tolerated, but isoxazoline-associated neurologic reactions, macrocyclic-lactone susceptibility, heartworm screening, young or underweight dogs and unestablished reproductive safety require deliberate case selection.

Clinical practicality8.5/10

A palatable monthly whole chew and clear weight bands are convenient in practice, but the tablet cannot be divided and the indication, body weight, heartworm status and treatment interval must be checked.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only when flea or tick control and one or more other labelled parasite targets are indicated simultaneously; avoid the fixed combination when one active component is unnecessary.
  • In heartworm-endemic areas, test dogs before administration; the product does not kill adult heartworms and infected dogs require specialist management.
  • Use caution in dogs with a history of seizures or neurologic disorders and strictly observe the recommended dose in Collies and related breeds.
  • For dogs younger than 8 weeks or below 1.35 kg, use only after an individual benefit-risk assessment; safety in breeding males and during pregnancy or lactation is not established.
Assessment sources
  1. VMD SPC 20262026
  2. EMA NexGard Spectra EPAR2025
  3. NexGard Spectra GI nematode RCTs2016
  4. NexGard Spectra lungworm RCT2016
  5. NexGard Spectra sarcoptic field study2018
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Afoxolaner18.75 mg Milbemycin oxime3.75 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Boehringer Ingelheim · Germany
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნექსგარდი სპექტრა ->3,5-7,5კგ ძაღლებისთვის
№ 41-11, 351-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
Dogs.
 Cat Any weight By mouth - Product label (SPC)
1 tablet
For dogs above 3.5–7.5 kg, give 1 NexGard Spectra 19 mg/4 mg tablet. Use only for mixed infestations. In Collies and related breeds, follow the dose exactly. Test first in heartworm-endemic areas. Do not divide the tablet.
 Dog 3.5–7.5 kg By mouth monthly Product label (SPC)
38 mg/8 mg, Chewable tablet · Cat Any weight Cat Any weight No dose for this species
Dogs.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნექსგარდი სპექტრა ->7,5-15კგ ძაღლებისთვის
№ 42-11, 452-11
Verified on: 15 Oct 2026
38 mg/8 mg, Chewable tablet · Dog 7.5–15 kg Dog 7.5–15 kg 1 tablet
For dogs above 7.5–15 kg, give 1 NexGard Spectra 38 mg/8 mg tablet. Use only for mixed infestations. In Collies and related breeds, follow the dose exactly. Test first in heartworm-endemic areas. Do not divide the tablet.
 · monthly		 monthly Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნექსგარდი სპექტრა ->7,5-15კგ ძაღლებისთვის
№ 42-11, 452-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

NexGard Spectra 38 mg/8 mg, Chewable tablet

afoxolaner 37.5 mg + milbemycin oxime 7.5 mg, chewable tablet for dogs 7.5-15 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.5/10
Very good
vetman assessment

NexGard Spectra

38 mg/8 mg, afoxolaner 37.5 mg + milbemycin oxime 7.5 mg, chewable tablet for dogs 7.5-15 kg
Assessed clinical scopeDog · Full labelled canine mixed-parasite scope, only when flea or tick control and one or more other labelled parasite targets are indicated at the same time · By mouth
Care settingVeterinary-selected monthly or indication-specific integrated parasite control after diagnosis and exposure-risk assessment
vetman score 8.5/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 42-11, 452-11 · Verified on 15 Oct 2026

A strong broad-spectrum canine option when ectoparasite control and an additional labelled nematode target coincide; avoid using the fixed combination when one component adds no clinical value.

Regulatory and scientific credibility9.5/10

All five exact weight bands are centrally authorised in the EU, covered by a current official SPC and registered in Georgia, with an extensive indication-specific evidence package.

Clinical efficacy9.0/10

Controlled and field studies support high efficacy across major labelled fleas, ticks, mites and nematodes, including heartworm and lungworm prevention; the fixed combination is justified only when both components are clinically needed.

Safety and tolerability7.0/10

Usually well tolerated, but isoxazoline-associated neurologic reactions, macrocyclic-lactone susceptibility, heartworm screening, young or underweight dogs and unestablished reproductive safety require deliberate case selection.

Clinical practicality8.5/10

A palatable monthly whole chew and clear weight bands are convenient in practice, but the tablet cannot be divided and the indication, body weight, heartworm status and treatment interval must be checked.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only when flea or tick control and one or more other labelled parasite targets are indicated simultaneously; avoid the fixed combination when one active component is unnecessary.
  • In heartworm-endemic areas, test dogs before administration; the product does not kill adult heartworms and infected dogs require specialist management.
  • Use caution in dogs with a history of seizures or neurologic disorders and strictly observe the recommended dose in Collies and related breeds.
  • For dogs younger than 8 weeks or below 1.35 kg, use only after an individual benefit-risk assessment; safety in breeding males and during pregnancy or lactation is not established.
Assessment sources
  1. VMD SPC 20262026
  2. EMA NexGard Spectra EPAR2025
  3. NexGard Spectra GI nematode RCTs2016
  4. NexGard Spectra lungworm RCT2016
  5. NexGard Spectra sarcoptic field study2018
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Afoxolaner37.5 mg Milbemycin oxime7.5 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Boehringer Ingelheim · Germany
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნექსგარდი სპექტრა ->7,5-15კგ ძაღლებისთვის
№ 42-11, 452-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
Dogs.
 Cat Any weight By mouth - Product label (SPC)
1 tablet
For dogs above 7.5–15 kg, give 1 NexGard Spectra 38 mg/8 mg tablet. Use only for mixed infestations. In Collies and related breeds, follow the dose exactly. Test first in heartworm-endemic areas. Do not divide the tablet.
 Dog 7.5–15 kg By mouth monthly Product label (SPC)
75 mg/15 mg, Chewable tablet · Cat Any weight Cat Any weight No dose for this species
Dogs.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნექსგარდი სპექტრა ->15-30კგ ძაღლებისთვის
№ 43-11, 352-11
Verified on: 15 Oct 2026
75 mg/15 mg, Chewable tablet · Dog 15–30 kg Dog 15–30 kg 1 tablet
For dogs above 15–30 kg, give 1 NexGard Spectra 75 mg/15 mg tablet. Use only for mixed infestations. In Collies and related breeds, follow the dose exactly. Test first in heartworm-endemic areas. Do not divide the tablet.
 · monthly		 monthly Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნექსგარდი სპექტრა ->15-30კგ ძაღლებისთვის
№ 43-11, 352-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

NexGard Spectra 75 mg/15 mg, Chewable tablet

afoxolaner 75 mg + milbemycin oxime 15 mg, chewable tablet for dogs 15-30 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.5/10
Very good
vetman assessment

NexGard Spectra

75 mg/15 mg, afoxolaner 75 mg + milbemycin oxime 15 mg, chewable tablet for dogs 15-30 kg
Assessed clinical scopeDog · Full labelled canine mixed-parasite scope, only when flea or tick control and one or more other labelled parasite targets are indicated at the same time · By mouth
Care settingVeterinary-selected monthly or indication-specific integrated parasite control after diagnosis and exposure-risk assessment
vetman score 8.5/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 43-11, 352-11 · Verified on 15 Oct 2026

A strong broad-spectrum canine option when ectoparasite control and an additional labelled nematode target coincide; avoid using the fixed combination when one component adds no clinical value.

Regulatory and scientific credibility9.5/10

All five exact weight bands are centrally authorised in the EU, covered by a current official SPC and registered in Georgia, with an extensive indication-specific evidence package.

Clinical efficacy9.0/10

Controlled and field studies support high efficacy across major labelled fleas, ticks, mites and nematodes, including heartworm and lungworm prevention; the fixed combination is justified only when both components are clinically needed.

Safety and tolerability7.0/10

Usually well tolerated, but isoxazoline-associated neurologic reactions, macrocyclic-lactone susceptibility, heartworm screening, young or underweight dogs and unestablished reproductive safety require deliberate case selection.

Clinical practicality8.5/10

A palatable monthly whole chew and clear weight bands are convenient in practice, but the tablet cannot be divided and the indication, body weight, heartworm status and treatment interval must be checked.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only when flea or tick control and one or more other labelled parasite targets are indicated simultaneously; avoid the fixed combination when one active component is unnecessary.
  • In heartworm-endemic areas, test dogs before administration; the product does not kill adult heartworms and infected dogs require specialist management.
  • Use caution in dogs with a history of seizures or neurologic disorders and strictly observe the recommended dose in Collies and related breeds.
  • For dogs younger than 8 weeks or below 1.35 kg, use only after an individual benefit-risk assessment; safety in breeding males and during pregnancy or lactation is not established.
Assessment sources
  1. VMD SPC 20262026
  2. EMA NexGard Spectra EPAR2025
  3. NexGard Spectra GI nematode RCTs2016
  4. NexGard Spectra lungworm RCT2016
  5. NexGard Spectra sarcoptic field study2018
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Afoxolaner75 mg Milbemycin oxime15 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Boehringer Ingelheim · Germany
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნექსგარდი სპექტრა ->15-30კგ ძაღლებისთვის
№ 43-11, 352-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
Dogs.
 Cat Any weight By mouth - Product label (SPC)
1 tablet
For dogs above 15–30 kg, give 1 NexGard Spectra 75 mg/15 mg tablet. Use only for mixed infestations. In Collies and related breeds, follow the dose exactly. Test first in heartworm-endemic areas. Do not divide the tablet.
 Dog 15–30 kg By mouth monthly Product label (SPC)
150 mg/30 mg, Chewable tablet · Cat Any weight Cat Any weight No dose for this species
Dogs.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნექსგარდი სპექტრა - >30-60კგ ძაღლებისთვის
№ 19-11, 338-11
Verified on: 15 Oct 2026
150 mg/30 mg, Chewable tablet · Dog 30–60 kg Dog 30–60 kg 1 tablet
appropriate combinations of chewable tablets should be used
 · monthly		 monthly Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნექსგარდი სპექტრა - >30-60კგ ძაღლებისთვის
№ 19-11, 338-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

NexGard Spectra 150 mg/30 mg, Chewable tablet

afoxolaner 150 mg + milbemycin oxime 30 mg, chewable tablet for dogs 30-60 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.5/10
Very good
vetman assessment

NexGard Spectra

150 mg/30 mg, afoxolaner 150 mg + milbemycin oxime 30 mg, chewable tablet for dogs 30-60 kg
Assessed clinical scopeDog · Full labelled canine mixed-parasite scope, only when flea or tick control and one or more other labelled parasite targets are indicated at the same time · By mouth
Care settingVeterinary-selected monthly or indication-specific integrated parasite control after diagnosis and exposure-risk assessment
vetman score 8.5/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 19-11, 338-11 · Verified on 15 Oct 2026

A strong broad-spectrum canine option when ectoparasite control and an additional labelled nematode target coincide; avoid using the fixed combination when one component adds no clinical value.

Regulatory and scientific credibility9.5/10

All five exact weight bands are centrally authorised in the EU, covered by a current official SPC and registered in Georgia, with an extensive indication-specific evidence package.

Clinical efficacy9.0/10

Controlled and field studies support high efficacy across major labelled fleas, ticks, mites and nematodes, including heartworm and lungworm prevention; the fixed combination is justified only when both components are clinically needed.

Safety and tolerability7.0/10

Usually well tolerated, but isoxazoline-associated neurologic reactions, macrocyclic-lactone susceptibility, heartworm screening, young or underweight dogs and unestablished reproductive safety require deliberate case selection.

Clinical practicality8.5/10

A palatable monthly whole chew and clear weight bands are convenient in practice, but the tablet cannot be divided and the indication, body weight, heartworm status and treatment interval must be checked.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only when flea or tick control and one or more other labelled parasite targets are indicated simultaneously; avoid the fixed combination when one active component is unnecessary.
  • In heartworm-endemic areas, test dogs before administration; the product does not kill adult heartworms and infected dogs require specialist management.
  • Use caution in dogs with a history of seizures or neurologic disorders and strictly observe the recommended dose in Collies and related breeds.
  • For dogs younger than 8 weeks or below 1.35 kg, use only after an individual benefit-risk assessment; safety in breeding males and during pregnancy or lactation is not established.
Assessment sources
  1. VMD SPC 20262026
  2. EMA NexGard Spectra EPAR2025
  3. NexGard Spectra GI nematode RCTs2016
  4. NexGard Spectra lungworm RCT2016
  5. NexGard Spectra sarcoptic field study2018
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Afoxolaner150 mg Milbemycin oxime30 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Boehringer Ingelheim · Germany
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ნექსგარდი სპექტრა - >30-60კგ ძაღლებისთვის
№ 19-11, 338-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
Dogs.
 Cat Any weight By mouth - Product label (SPC)
1 tablet
appropriate combinations of chewable tablets should be used
 Dog 30–60 kg By mouth monthly Product label (SPC)
Active substance doses, with sources
Active substance Afoxolaner
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
2.5–6.94 mg/kg Dog Maintenance By mouth monthly
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
NexGard Spectra 9 mg / 2 mg chewable tablets for dogs 1.35-3.5 kg - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
Active substance Milbemycin oxime
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
0.5 mg/kg Dog Maintenance By mouth once
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Milpro 2.5 mg/25 mg film-coated tablets for small dogs and puppies - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
2 mg/kg Cat Maintenance By mouth once
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Milpro 4 mg/10 mg film-coated tablets for small cats and kittens - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025

Known Contraindications

  • Critical Afoxolaner
    Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
    Sources: VMD SPC · VMD
  • Warning Afoxolaner (Dog)
    In the absence of available data, treatment of puppies less than 8 weeks of age and dogs less than 1.35 kg bodyweight should be based on a benefit-risk assessment by the responsible veterinarian. The safety of NexGard has not been evaluated in dogs less than 8 weeks of age or less than 4 lbs body weight.
    Sources: VMD SPC · VMD · FDA
  • Caution Afoxolaner (Dog)
    Afoxolaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Neurological signs (convulsion, ataxia and muscle tremor).
    Sources: VMD SPC · VMD · FDA
  • Critical Milbemycin oxime
    Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
    Sources: VMD SPC · VMD
  • Critical Milbemycin oxime
    Severe kidney impairment: one product label lists marked kidney or liver dysfunction as a contraindication. Another notes that no studies exist in severely debilitated dogs or in animals with seriously impaired kidney or liver function, and does not recommend use in them, or only after a benefit-risk assessment.
    Sources: VMD SPC · VMD
  • Critical Milbemycin oxime
    Severe liver impairment: one product label lists marked kidney or liver dysfunction as a contraindication. Another does not recommend use in animals with seriously impaired kidney or liver function, or only after a benefit-risk assessment.
    Sources: VMD SPC · VMD
  • Critical Milbemycin oxime (Dog)
    Do not use in puppies of less than 2 weeks of age and/or weighing less than 0.5 kg.
    Sources: VMD SPC · VMD
  • Critical Milbemycin oxime (Cat)
    Do not use in kittens of less than 6 weeks of age and/or weighing less than 0.5 kg.
    Sources: VMD SPC · VMD
  • Warning Milbemycin oxime
    Emaciated, severely debilitated animals and animals with an infectious disease: one product label excludes them from deworming; another does not recommend use in severely debilitated animals, or only after a benefit-risk assessment.
    Sources: VMD SPC · VMD
  • Warning Milbemycin oxime (Dog)
    the margin of safety in certain dogs of Collie or related breeds is less than in other breeds. In these dogs, the recommended dose should be strictly observed. The tolerance of the veterinary medicinal product in young puppies from these breeds has not been investigated.
    Sources: VMD SPC · VMD
  • Warning Milbemycin oxime (Dog)
    The use in dogs suffering from microfilaremia is thus not recommended. In the case of a positive diagnosis, adulticidal therapy is indicated before administering the veterinary medicinal product.
    Sources: VMD SPC · VMD
  • Caution Milbemycin oxime
    In a study, this combination of active substances was demonstrated to be well tolerated in breeding bitches, including during pregnancy and lactation. As a specific study with this veterinary medicinal product has not been performed, use during pregnancy and lactation only according to the benefit-risk assessment
    Sources: VMD SPC · VMD
  • Caution Milbemycin oxime
    use during pregnancy and lactation only according to the benefit-risk assessment by the responsible veterinarian.
    Sources: VMD SPC · VMD
  • Caution Milbemycin oxime (Cat)
    In the absence of data on cats with microfilaraemia, its use should be according to a benefit risk assessment by the attending veterinarian.
    Sources: VMD SPC · VMD
  • Known Breed Sensitivities Milbemycin oxime
    Collie, Collie (unspecified), Collie - Scottish Rough, Collie - Scottish Smooth, Sheepdog - Old English, Sheepdog - Shetland (Sheltie), Shetland Sheepdog
    the margin of safety in certain dogs of Collie or related breeds is less than in other breeds. In these dogs, the recommended dose should be strictly observed.

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (80 more) Hide additional products

Same therapeutic group 80

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗